Sodium stibogluconate

Drug Profile

Sodium stibogluconate

Alternative Names: Lenocta; SSG; VQD-001

Latest Information Update: 05 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Greenwich Therapeutics
  • Developer University of Texas M. D. Anderson Cancer Center; VioQuest Pharmaceuticals; Walter Reed Army Medical Center
  • Class Antineoplastics; Antiprotozoals; Small molecules
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous leishmaniasis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cutaneous leishmaniasis; Solid tumours

Most Recent Events

  • 12 Feb 2010 A phase I/II trial in Advanced malignancies completed in USA
  • 10 Oct 2007 Clinical data added to the adverse events and Cancer pharmacodynamics sections
  • 10 Oct 2007 VioQuest completes enrolment in its phase I trial for Solid tumours in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top